ApoB-containing lipoproteins as the causal driver of atherosclerosis (EAS Consensus)

If modern preventive cardiology has a central dogma, this European Atherosclerosis Society consensus is its clearest statement: ApoB-containing lipoproteins don’t just associate with heart disease — they cause it, and the damage is cumulative.

The mechanism the panel synthesizes is the “response-to-retention” model. Any ApoB particle small enough to cross the artery lining — LDL, Lp(a), and triglyceride-rich remnants alike — can become trapped in the wall, where it triggers the inflammatory cascade that builds plaque. From there follows the consequential claim, drawn from genetics, epidemiology, and randomized trials in concert: risk is set by cumulative exposure to these particles — how high, multiplied by how long — and lowering them cuts risk in proportion to the absolute reduction, regardless of which drug does the lowering.

The practical takeaways reshape strategy: measure ApoB (or non-HDL-C), treat to get the particle burden as low as feasible, and start earlier in life, because every year of exposure counts. The resistance is the older “threshold” mindset — treat only once a number crosses a line — that the lifetime-exposure model overturns.

We rate the evidence at the top of the scale: a consensus built on concordant genetic, observational, and randomized data spanning millions of people, where the causal role of ApoB/LDL is now treated as biological fact. Its clinical significance is as high as it gets — this is the paradigm that defines how risk is calculated and treated across the at-risk population.

(Note: this source’s bibliographic metadata in our library is incomplete; the analysis reflects the documented EAS consensus on ApoB-driven atherogenesis. Verify the exact citation against the DOI before formal use.)